<DOC>
	<DOC>NCT00648284</DOC>
	<brief_summary>The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.</brief_summary>
	<brief_title>Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition Have signed informed consent Patients with ALT &gt; 2.5x the normal value With heart failure symptoms With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates With recent myocardial infarction (&lt;6 months) With severe renal disfunction Pregnant or lactating or planned to be pregnant during the study Under investigational drug treatment Alcoholic or drug abuser</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>CV risk</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>AVANDIA</keyword>
</DOC>